BioCentury
ARTICLE | Company News

ConverGene, NIH deal

April 14, 2017 4:32 PM UTC

ConverGene and NIH’s National Institute of Neurological Disorders and Stroke (NINDS) partnered to optimize and develop antagonists of dopamine D2 receptors, including lead molecules in ConverGene's preclinical CVG-101 program. According to ConverGene's website, the lead molecules include: dual BET bromodomain protein/dopamine D2 receptor antagonists CG223 and CG250 which are in development to treat solid tumors; BET antagonist CG202 which is in development to treat liquid tumors; and psychiatric disorders candidate CG209, a dopamine D2 receptor antagonist. The partnership falls under a cooperative research and development agreement (CRADA)...